Gut Microbiota Interactions in Liver Diseases

The gut microbiota and its interactions with the liver constitute a dynamic axis that shapes the development and progression of a broad spectrum of liver disorders, including non-alcoholic fatty liver disease, alcoholic steatohepatitis, cirrhosis and hepatocellular carcinoma. Microbial communities in the intestine metabolise nutrients and produce bioactive compounds such as bile acids and short-chain fatty acids, which influence hepatic energy homeostasis, immune regulation and inflammatory responses. Perturbations in microbial composition—often termed dysbiosis—can compromise the intestinal barrier, permitting microbial translocation and systemic endotoxaemia that amplify liver injury. Signals conveyed via the portal vein and biliary tract establish a bidirectional dialogue that determines both microbial ecology and liver function. Advances in this field have identified mechanistic pathways, biomarker candidates and potential microbiome-based therapies to mitigate chronic liver disease on a global scale.

Research from Nature Portfolio

Recent studies have characterised gut dysbiosis in non-alcoholic fatty liver disease-related hepatocellular carcinoma, revealing that specific microbial metabolites modulate systemic immunity and foster tumour immune evasion. Distinct patterns of short-chain fatty acid production accompany expansion of regulatory T cells and suppression of cytotoxic CD8+ lymphocytes, linking microbial function to cancer progression. Another seminal finding demonstrated that use of proton pump inhibitors promotes overgrowth of intestinal Enterococcus species, driving their translocation to the liver, exacerbating hepatic inflammation and hepatocyte death. These insights delineate microbiota-driven mechanisms underpinning disease progression and highlight microbial pathways as candidate targets for intervention.

Gut Microbiota Interactions in Liver Diseases publication trend

The graph below shows the total number of articles in gut microbiota interactions in liver diseases across all publications each year (not limited to Nature Index journals).

Technical terms

Gut microbiota: The community of microorganisms residing in the gastrointestinal tract.

Gut–liver axis: Bidirectional communication pathway between the intestine and the liver via blood flow, bile acids and immune signals.

Dysbiosis: Disruption of the normal balance and diversity of gut microbial communities.

Short-chain fatty acids: Metabolites produced by microbial fermentation of dietary fibres that influence host energy metabolism and immunity.

Translocation: Passage of bacteria or bacterial products across the gut barrier into systemic circulation or the liver.

Regulatory T cells: A subset of T lymphocytes that suppress immune responses and maintain tolerance.

Portal circulation: The venous blood flow that carries nutrients and microbial molecules from the gut to the liver.

Hepatocellular carcinoma: The most common form of primary liver cancer arising from hepatocytes.

References

1. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature. International Journal of Molecular Sciences (2019).
2. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Nature Communications (2021).
3. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nature Communications (2017).
4. Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma. Gut Pathogens (2019).
5. Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma. Genome Medicine (2020).